In step toward personalized medicine, FDA approves BiDil

Taking what it described as a step toward personalized medicine, the FDA has approved NitroMed's Bidil, a heart medication that was successful in trials involving African-Americans. The drug has aroused intense controversy as some critics contend that a drug designed exclusively for blacks could reignite racist arguments about the biological differences of whites and blacks. Medical experts, though, contend that the approval provides blacks with a significant new therapy. And the FDA maintains that they are ready to examine drugs that are effective in other groups regardless of race.

- read this article from The Washington Post

ALSO: The FDA has also approved UCB Pharma's Keppra for epilepsy. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.